Santhera's AGAMREE® Approved for Duchenne Muscular Dystrophy Care

Santhera Pharmaceuticals has announced that the Chinese National Medical Products Administration (NMPA) has approved AGAMREE® (vamorolone) for patients aged 4 years and older in China. 

AGAMREE is a groundbreaking therapy with a unique mechanism of action. It binds to the same receptor as glucocorticoids but modifies the receptor's downstream activity, distinguishing itself from traditional corticosteroids. 

This distinctive mechanism enables AGAMREE to deliver therapeutic benefits while reducing safety concerns typically associated with steroids, positioning it as a dissociative anti-inflammatory and a novel alternative to standard corticosteroids for children and adolescents with Duchenne muscular dystrophy (DMD).

In the pivotal VISION-DMD study, AGAMREE achieved its primary endpoint by significantly improving the standing-to-stand speed (TTSTAND) compared to placebo (p=0.002) after 24 weeks of treatment. It also demonstrated a favourable safety and tolerability profile, with the most common adverse events being Cushingoid appearance, vomiting, weight gain, and irritability—generally mild to moderate in severity.

AGAMREE marks a milestone as the first and only approved treatment for DMD in China. This approval follows the acceptance of the New Drug Application (NDA) by the NMPA in March 2024. The NDA highlighted AGAMREE’s clinically significant safety benefits, including the maintenance of normal bone metabolism, density, and growth, compared to traditional corticosteroids. 

DMD is a debilitating condition that affects over 70,000 individuals in China. Until now, there were no approved treatment options for this patient population, making AGAMREE's approval a significant advancement in addressing this critical unmet need.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!